Details
Stereochemistry | ACHIRAL |
Molecular Formula | C7H8O2 |
Molecular Weight | 124.1372 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=CC=C(O)C=C1
InChI
InChIKey=NWVVVBRKAWDGAB-UHFFFAOYSA-N
InChI=1S/C7H8O2/c1-9-7-4-2-6(8)3-5-7/h2-5,8H,1H3
Molecular Formula | C7H8O2 |
Molecular Weight | 124.1372 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Mequinol (mequinol is 4-hydroxyanisole) is an active ingredient in topical drugs used for skin depigmentation. The mechanism of action of mequinol is unknown. Although mequinol is a substrate for the enzyme tyrosinase and acts as a competitive inhibitor of the formation of melanin precursors, the clinical significance of these findings is unknown.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL1973 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | SOLAGE Approved UseMequinol is a depigmenting agent. The mechanism of depigmenting effects of mequinol remain unclear; speculations include oxidation by tyrosinase to cytotoxic products in melanocytes, a direct/selective toxic effect on melanocytes, or inhibition of melanin formation Launch Date1999 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
9.92 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/10701701/ |
16 μL 1 times / day steady-state, topical dose: 16 μL route of administration: Topical experiment type: STEADY-STATE co-administered: |
MEQUINOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
33.43 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/10701701/ |
16 μL 1 times / day steady-state, topical dose: 16 μL route of administration: Topical experiment type: STEADY-STATE co-administered: |
MEQUINOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
5 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/10701701/ |
16 μL 1 times / day steady-state, topical dose: 16 μL route of administration: Topical experiment type: STEADY-STATE co-administered: |
MEQUINOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
2 % 1 times / day steady, topical Recommended Dose: 2 %, 1 times / day Route: topical Route: steady Dose: 2 %, 1 times / day Co-administed with:: tretinoin(0.0001) Sources: |
healthy, 55.8 years n = 159 Health Status: healthy Condition: solar lentigines Age Group: 55.8 years Sex: M+F Population Size: 159 Sources: |
Disc. AE: Dermal and epidermal conditions NEC, Skin and subcutaneous tissue disorders... Other AEs: Hematuria... AEs leading to discontinuation/dose reduction: Dermal and epidermal conditions NEC (3.5%) Other AEs:Skin and subcutaneous tissue disorders (5.8%) Hematuria (3.5%) Sources: |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Hematuria | 3.5% | 2 % 1 times / day steady, topical Recommended Dose: 2 %, 1 times / day Route: topical Route: steady Dose: 2 %, 1 times / day Co-administed with:: tretinoin(0.0001) Sources: |
healthy, 55.8 years n = 159 Health Status: healthy Condition: solar lentigines Age Group: 55.8 years Sex: M+F Population Size: 159 Sources: |
Dermal and epidermal conditions NEC | 3.5% Disc. AE |
2 % 1 times / day steady, topical Recommended Dose: 2 %, 1 times / day Route: topical Route: steady Dose: 2 %, 1 times / day Co-administed with:: tretinoin(0.0001) Sources: |
healthy, 55.8 years n = 159 Health Status: healthy Condition: solar lentigines Age Group: 55.8 years Sex: M+F Population Size: 159 Sources: |
Skin and subcutaneous tissue disorders | 5.8% Disc. AE |
2 % 1 times / day steady, topical Recommended Dose: 2 %, 1 times / day Route: topical Route: steady Dose: 2 %, 1 times / day Co-administed with:: tretinoin(0.0001) Sources: |
healthy, 55.8 years n = 159 Health Status: healthy Condition: solar lentigines Age Group: 55.8 years Sex: M+F Population Size: 159 Sources: |
PubMed
Title | Date | PubMed |
---|---|---|
Depigmentation therapy in vitiligo universalis with topical 4-methoxyphenol and the Q-switched ruby laser. | 2000 May |
|
Enhancement of the depigmenting effect of hydroquinone and 4-hydroxyanisole by all-trans-retinoic acid (tretinoin): the impairment of glutathione-dependent cytoprotection? | 2003 |
|
Anise oil as para-methoxyamphetamine (PMA) precursor. | 2003 Apr 23 |
|
Arrest of cell cycle by inhibition of ribonucleotide reductase induces accumulation of NAD+ by Mn2+-supplemented growth of Corynebacterium ammoniagenes. | 2003 Jan |
|
Antioxidant activity and characterization of volatile constituents of Taheebo (Tabebuia impetiginosa Martius ex DC). | 2003 Jan 1 |
|
[Hygienic standards of the occupational air quality established by the Experts on Chemical Agents, 2002]. | 2004 |
|
On the etiology of contact/occupational vitiligo. | 2004 Jun |
|
Purification and characterization of tyrosinase from gill tissue of Portabella mushrooms. | 2004 Mar |
|
Structural close-related aromatic compounds have different effects on laccase activity and on lcc gene expression in the ligninolytic fungus Trametes sp. I-62. | 2004 Oct |
|
Correlation of in vitro chemopreventive efficacy data from the human epidermal cell assay with animal efficacy data and clinical trial plasma levels. | 2005 Jun 1 |
|
Site-specific H/D exchange of p-methoxyphenol studied by resonant two-photon ionization and mass-analyzed threshold ionization spectroscopy. | 2005 Oct 27 |
|
An investigation of the reduction in aqueous acetonitrile of 4-methoxybenzenediazonium ion by the tetrakis(acetonitrile)Cu(I) cation catalysed by hydrogenphosphate dianion. | 2007 Feb 21 |
|
Separation of molecular tracers sorbed onto atmospheric particulate matter by flash chromatography. | 2007 Mar |
|
A novel melanin inhibitor: hydroperoxy traxastane-type triterpene from flowers of Arnica montana. | 2007 May |
|
Quantification of organic eluates from polymerized resin-based dental restorative materials by use of GC/MS. | 2007 May 1 |
|
Subcellular localization and cytoplasmic complex status of endogenous Keap1. | 2007 Oct |
|
Electrochemical oxidation characteristics of p-substituted phenols using a boron-doped diamond electrode. | 2007 Sep 15 |
|
Efficient synthesis and properties of novel near-infrared electrochromic anthraquinone imides. | 2008 Feb 21 |
|
Increase in the levels of chaperone proteins by exposure to beta-estradiol, bisphenol A and 4-methoxyphenol in human cells transfected with estrogen receptor alpha cDNA. | 2009 Jun |
|
In vivo anti-inflammatory action of eugenol on lipopolysaccharide-induced lung injury. | 2010 Apr |
|
Pi-selective stationary phases: (II) Adsorption behaviour of substituted aromatic compounds on n-alkyl-phenyl stationary phases. | 2010 Aug 13 |
|
Depigmentation therapy in vitiligo universalis with cryotherapy and 4-hydroxyanisole. | 2010 Mar |
Patents
Sample Use Guides
Apply Solagé to the solar lentigines using the applicator tip while avoiding application to the surrounding skin. Use twice daily, morning and evening at least 8 hours apart, or as directed by a physician. Patients should not shower or bathe the treatment areas for at least 6 hours after application of Solagé. Special caution should be taken when applying Solagé to avoid the eyes, mouth, paranasal creases, and mucous membranes.
Route of Administration:
Topical
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:00:06 GMT 2023
by
admin
on
Fri Dec 15 15:00:06 GMT 2023
|
Record UNII |
6HT8U7K3AM
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C78284
Created by
admin on Fri Dec 15 15:00:06 GMT 2023 , Edited by admin on Fri Dec 15 15:00:06 GMT 2023
|
||
|
NDF-RT |
N0000175851
Created by
admin on Fri Dec 15 15:00:06 GMT 2023 , Edited by admin on Fri Dec 15 15:00:06 GMT 2023
|
||
|
WHO-ATC |
D11AX06
Created by
admin on Fri Dec 15 15:00:06 GMT 2023 , Edited by admin on Fri Dec 15 15:00:06 GMT 2023
|
||
|
NDF-RT |
N0000175855
Created by
admin on Fri Dec 15 15:00:06 GMT 2023 , Edited by admin on Fri Dec 15 15:00:06 GMT 2023
|
||
|
NDF-RT |
N0000175850
Created by
admin on Fri Dec 15 15:00:06 GMT 2023 , Edited by admin on Fri Dec 15 15:00:06 GMT 2023
|
||
|
CFR |
21 CFR 176.170
Created by
admin on Fri Dec 15 15:00:06 GMT 2023 , Edited by admin on Fri Dec 15 15:00:06 GMT 2023
|
||
|
WHO-VATC |
QD11AX06
Created by
admin on Fri Dec 15 15:00:06 GMT 2023 , Edited by admin on Fri Dec 15 15:00:06 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DB09516
Created by
admin on Fri Dec 15 15:00:06 GMT 2023 , Edited by admin on Fri Dec 15 15:00:06 GMT 2023
|
PRIMARY | |||
|
150-76-5
Created by
admin on Fri Dec 15 15:00:06 GMT 2023 , Edited by admin on Fri Dec 15 15:00:06 GMT 2023
|
PRIMARY | |||
|
CHEMBL544
Created by
admin on Fri Dec 15 15:00:06 GMT 2023 , Edited by admin on Fri Dec 15 15:00:06 GMT 2023
|
PRIMARY | |||
|
4258
Created by
admin on Fri Dec 15 15:00:06 GMT 2023 , Edited by admin on Fri Dec 15 15:00:06 GMT 2023
|
PRIMARY | |||
|
15080
Created by
admin on Fri Dec 15 15:00:06 GMT 2023 , Edited by admin on Fri Dec 15 15:00:06 GMT 2023
|
PRIMARY | RxNorm | ||
|
6HT8U7K3AM
Created by
admin on Fri Dec 15 15:00:06 GMT 2023 , Edited by admin on Fri Dec 15 15:00:06 GMT 2023
|
PRIMARY | |||
|
1542
Created by
admin on Fri Dec 15 15:00:06 GMT 2023 , Edited by admin on Fri Dec 15 15:00:06 GMT 2023
|
PRIMARY | |||
|
6827
Created by
admin on Fri Dec 15 15:00:06 GMT 2023 , Edited by admin on Fri Dec 15 15:00:06 GMT 2023
|
PRIMARY | |||
|
205-769-8
Created by
admin on Fri Dec 15 15:00:06 GMT 2023 , Edited by admin on Fri Dec 15 15:00:06 GMT 2023
|
PRIMARY | |||
|
SUB08764MIG
Created by
admin on Fri Dec 15 15:00:06 GMT 2023 , Edited by admin on Fri Dec 15 15:00:06 GMT 2023
|
PRIMARY | |||
|
DTXSID4020828
Created by
admin on Fri Dec 15 15:00:06 GMT 2023 , Edited by admin on Fri Dec 15 15:00:06 GMT 2023
|
PRIMARY | |||
|
100000081706
Created by
admin on Fri Dec 15 15:00:06 GMT 2023 , Edited by admin on Fri Dec 15 15:00:06 GMT 2023
|
PRIMARY | |||
|
LL-42
Created by
admin on Fri Dec 15 15:00:06 GMT 2023 , Edited by admin on Fri Dec 15 15:00:06 GMT 2023
|
PRIMARY | |||
|
C47604
Created by
admin on Fri Dec 15 15:00:06 GMT 2023 , Edited by admin on Fri Dec 15 15:00:06 GMT 2023
|
PRIMARY | |||
|
4221
Created by
admin on Fri Dec 15 15:00:06 GMT 2023 , Edited by admin on Fri Dec 15 15:00:06 GMT 2023
|
PRIMARY | |||
|
C009760
Created by
admin on Fri Dec 15 15:00:06 GMT 2023 , Edited by admin on Fri Dec 15 15:00:06 GMT 2023
|
PRIMARY | |||
|
4960
Created by
admin on Fri Dec 15 15:00:06 GMT 2023 , Edited by admin on Fri Dec 15 15:00:06 GMT 2023
|
PRIMARY | |||
|
9015
Created by
admin on Fri Dec 15 15:00:06 GMT 2023 , Edited by admin on Fri Dec 15 15:00:06 GMT 2023
|
PRIMARY | |||
|
MEQUINOL
Created by
admin on Fri Dec 15 15:00:06 GMT 2023 , Edited by admin on Fri Dec 15 15:00:06 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |